Amphastar Pharmaceuticals Retained Earnings 2011-2026 | AMPH

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings Amphastar Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
667 M	569 M	409 M	272 M	180 M	118 M	116 M	67.5 M	76.2 M	70.9 M	60.3 M	63.1 M	73.8 M	61.9 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
667 M	60.3 M	200 M

Quarterly Retained Earnings Amphastar Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
642 M	625 M	594 M	569 M	531 M	490 M	-	409 M	373 M	-	298 M	272 M	-	222 M	205 M	180 M	161 M	131 M	123 M	118 M	118 M	118 M	118 M	116 M	116 M	116 M	116 M	67.5 M	67.5 M	67.5 M	67.5 M	72.6 M	72.6 M	76.2 M	76.2 M	70.9 M	70.9 M	70.9 M	70.9 M	60.3 M	60.3 M	60.3 M	60.3 M	63.1 M	63.1 M	63.1 M	63.1 M	73.8 M	73.8 M	73.8 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
642 M	60.3 M	177 M

Retained Earnings of other stocks in the Biotechnology industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
Precigen PGEN	-2.34 B	$ 3.1	-0.96 %	$ 758 M	USA
MorphoSys AG MOR	-158 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-335 M	-	5.93 %	$ 314 M	Canada
Akero Therapeutics AKRO	-826 M	-	-	$ 3.67 B	USA
Akouos AKUS	-168 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	-8.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	5.24 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	-405 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	-301 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	-17.1 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	-611 M	$ 220.9	2.49 %	$ 5 B	Danmark
Aileron Therapeutics ALRN	-351 M	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	-122 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-108 M	-	-1.52 %	$ 24.7 M	USA
Applied Genetic Technologies Corporation AGTC	-308 M	-	-	$ 26.5 M	USA
AgeX Therapeutics AGE	-63.5 M	-	-10.17 %	$ 12.2 K	USA
Aptinyx APTX	-353 M	-	-39.0 %	$ 4.57 M	USA
Acorda Therapeutics ACOR	-1.19 B	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-221 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	69.4 M	-	-	-	Russia
Adverum Biotechnologies ADVM	-1.07 B	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-141 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-197 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	-149 M	-	-	$ 7.46 M	Israel
Avenue Therapeutics ATXI	-103 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-1.1 B	$ 1.33	0.76 %	$ 339 M	Britain
Atreca BCEL	-457 M	-	-11.76 %	$ 5.79 M	USA
BeiGene, Ltd. BGNE	-8.32 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-4.26 B	-	-	$ 546 M	USA
ProQR Therapeutics N.V. PRQR	-258 M	$ 1.58	6.04 %	$ 99.5 M	Niderland
BioDelivery Sciences International BDSI	-256 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	-685 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-617 M	-	-	$ 3.74 B	USA
Aeglea BioTherapeutics AGLE	-1.13 B	-	-	$ 1.01 B	USA
Avid Bioservices CDMO	-572 M	-	-	$ 789 M	USA
CureVac N.V. CVAC	-1.06 B	-	-	$ 867 M	Germany
Bellerophon Therapeutics BLPH	-252 M	-	-74.18 %	$ 955 K	USA
Corbus Pharmaceuticals Holdings CRBP	-555 M	$ 8.31	1.59 %	$ 111 M	USA
CRISPR Therapeutics AG CRSP	-1.95 B	$ 47.09	1.42 %	$ 4.23 B	Schweiz
Arbutus Biopharma Corporation ABUS	-1.38 B	$ 4.53	5.1 %	$ 868 M	Canada
AIkido Pharma AIKI	-223 M	-	1.93 %	$ 17.4 M	USA
Allakos ALLK	-1.12 B	-	-	$ 28.6 M	USA
Brickell Biotech BBI	-172 M	-	-5.38 %	$ 6.06 M	USA
CytomX Therapeutics CTMX	-712 M	$ 4.22	-0.47 %	$ 582 M	USA
Allena Pharmaceuticals ALNA	-246 M	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	-491 M	-	-10.95 %	$ 876 K	USA
Alpine Immune Sciences ALPN	-224 M	-	-	$ 2.17 B	USA
Cyclacel Pharmaceuticals CYCC	-439 M	-	-5.98 %	$ 34.1 M	USA